Free tool
FAERS Monitor: Topotecan Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 200582 or its brand name (Topotecan Hydrochloride, Topotecan Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
5,353
Serious
5,108
95% of reports
Hospitalization
2,147
Death reported
1,065
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use551
- febrile neutropenia530
- neutropenia472
- anaemia415
- disease progression382
- pyrexia370
- vomiting361
- product use in unapproved indication360
- thrombocytopenia359
- nausea318
- malignant neoplasm progression296
- drug ineffective267
- pancytopenia250
- diarrhoea248
- fatigue241
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 81 |
| 2005 | 135 |
| 2006 | 88 |
| 2007 | 121 |
| 2008 | 107 |
| 2009 | 137 |
| 2010 | 162 |
| 2011 | 189 |
| 2012 | 184 |
| 2013 | 129 |
| 2014 | 185 |
| 2015 | 281 |
| 2016 | 302 |
| 2017 | 281 |
| 2018 | 323 |
| 2019 | 256 |
| 2020 | 388 |
| 2021 | 425 |
| 2022 | 368 |
| 2023 | 312 |
| 2024 | 323 |
| 2025 | 383 |
| 2026 | 193 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,806 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 530 | 31.6 | 29.2 | 15,618 |
| pancytopeniaSignal | 250 | 17.7 | 15.6 | 3,903 |
| neutropeniaSignal | 472 | 13.7 | 12.6 | 5,553 |
| disease progressionSignal | 382 | 12.7 | 11.5 | 4,124 |
| thrombocytopeniaSignal | 359 | 12.7 | 11.4 | 3,849 |
| malignant neoplasm progressionSignal | 296 | 11.4 | 10.2 | 2,800 |
| anaemiaSignal | 415 | 8.6 | 7.8 | 2,785 |
| product use in unapproved indicationSignal | 360 | 5.7 | 5.2 | 1,410 |
| pyrexiaSignal | 370 | 4.2 | 3.8 | 915 |
| vomitingSignal | 361 | 3.0 | 2.7 | 496 |
| off label useSignal | 551 | 2.5 | 2.3 | 503 |
| nausea | 318 | 1.6 | 1.4 | 70 |
| diarrhoea | 248 | 1.5 | 1.3 | 43 |
| fatigue | 241 | 1.2 | 1.1 | 9 |
| drug ineffective | 267 | 0.8 | 0.7 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.